Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

High-throughput neurovascular-unit-on-a-chip with OASIS for modeling Parkinson's disease

Award Number: R01NS133965
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2029

Group Awards By:

View Award Description

High-throughput neurovascular-unit-on-a-chip with OASIS for modeling Parkinson's disease - PROJECT SUMMARY Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, affecting nearly one million people in the United States as of 2020. The core etiopathology comprises intracellular accumulation of Lewy body-like α-synuclein (α-syn), followed by progressive loss of motor-controlling midbrain dopaminergic (mDA) neurons in the substantia nigra pars compacta. There is growing evidence that the dysfunction of the cerebral vasculature called the blood-brain barrier (BBB) is involved in PD progression and, more importantly, implicated in altered drug efficacy. PD patients suffer from a wide spectrum of clinical syndromes such as movement disorders/parkinsonism, dementia, and autonomic nervous system dysfunction. Current standards-of-care are not curative and focus on symptom management. Thus, a treatment option that can modify the disease pathology is sorely needed. One of the major challenges in developing such a therapy is the absence of an experimental model recapitulating human PD pathology, which is needed for quick and reliable screening of candidate therapies prior to clinical evaluation. Even though recent advances in human induced pluripotent stem cell (hiPSC) technology makes it possible to derive mDA neurons of PD patients, current 2D culture models do not recapitulate the native microenvironment around the neurovascular unit and thus cannot model the pathophysiology of late-onset human PD, which is induced by accumulated aberrant α-syn aggregation. To this end, we will develop and validate an advanced high-throughput in vitro human PD model that reflects pathological vascular and tissue changes observed in the brains of PD patients. Specifically, we will engineer and optimize a multi-well microfluidic tissue on-a-chip platform integrated with vascular perfusion and a blue light module to reconstruct the complex microenvironment at the interface of the human neurovascular unit and parenchyma tissue in human brains (Aim 1). We will then induce the core etiopathology of brain-borne α-syn aggregation in the PD patient-derived mDA neurons using our novel light-inducible pathogenic protein aggregation system (i.e., optogenetics-assisted alpha-synuclein aggregation induction system, OASIS) and α-syn preformed fibrils (Aim 2.1). In parallel, we will investigate the effect of blood-borne pathogenic α-syn aggregates, observed in patients, on PD progression in our model (Aim 2.2). We will validate our newly engineered human PD model by its comparison to clinical observations, including α-syn accumulation, neuroinflammation, progressive neuronal death, and pathological changes of the BBB. Finally, we will demonstrate that our PD model can serve as a testbed to evaluate the delivery efficiency and therapeutic efficacy of highly versatile drug-loaded delivery platforms (i.e., human ferritin nanocages) (Aim 3). If successful, the developed platform will ultimately allow us to build patient-specific disease models instrumental to the development of personalized medicines to treat PD patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $579,729 )
2026	2026	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	3/23/2026	NON-COMPETING CONTINUATION	$579,729
														Subtotal = $579,729

Issue Date FY: 2025 ( Subtotal = $581,422 )
2025	2025	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	4/30/2025	NON-COMPETING CONTINUATION	$581,422
														Subtotal = $581,422

Issue Date FY: 2024 ( Subtotal = $590,144 )
2024	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	2/26/2024	NEW	$590,144
														Subtotal = $590,144

Grand Total All Awards = $1,751,295

Top

All Categories

About

Search

Reports

Data Submission

Award Information

High-throughput neurovascular-unit-on-a-chip with OASIS for modeling Parkinson's disease

Award Number: R01NS133965

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer